Greece at a critical turning point Will Greece keep up with pharmaceutical innovation or be left behind? The event of Pharma Innovation Forum Greece (PIF), held on Wednesday, November 26, highlighted a reality that concerns us all: pharmaceutical innovation is advancing faster than ever. The question is whether Greece can -and wants to- keep up.…
The 2nd interactive workshop organized by PIF and ELLoK highlighted practical steps, institutional proposals and the importance of active citizen participation in the new era of health data. The Hellenic Cancer Federation (ELLOK), as the National Cancer Mission Hub (NCMH) of the European Mission on Cancer, in collaboration with Pharma Innovation Forum Greece (PIF) and…
At the initiative of PhARMA Innovation Forum (PIF), a broad meeting was held with the Minister of Health, Mr. Adonis Georgiadis, with the participation of SFEE and other institutional pharmaceutical bodies, in a productive and positive atmosphere, with a shared recognition of the pressure exerted by the clawback on patients and the innovation ecosystem. The…
A dialogue between PIF and ENASEL on the truth behind access to innovation. As part of the ENASEL 2025 Annual Patient Conference, the session titled “Access to Innovation Under Threat: Debunking Myths, Revealing Facts” was successfully held, co-organized by PhARMA Innovation Forum (PIF) and ENASEL. The initiative aimed to highlight, through evidence-based dialogue and data…
Imagine a patient with a rare condition in Greece who waits for years to access a new therapy. This is not an exception: reimbursement of innovative treatments in Greece is slow and only a small proportion of new therapies is available. The human cost is real. Yet biopharmaceutical science is advancing rapidly: international authorities classify…
Pharmaceutical innovation is more than a scientific or medical achievement—it is a strategic enabler for improving health outcomes, ensuring the sustainability of national healthcare systems, and driving economic growth. In Greece, this reality is becoming increasingly clear. With a population facing growing healthcare needs, limited resources, and mounting economic pressures, the integration of innovative therapies…
Biopharmaceutical research is advancing at an impressive pace, offering cutting-edge therapies that are transforming healthcare, altering the natural course of many severe diseases, and significantly improving patients’ quality of life. This progress makes pharmaceutical policy a decisive factor for the efficiency and resilience of the healthcare system, necessitating a structural revision that ensures innovation is…
“We want a Europe that does not just legislate, but truly innovates!” Ms. Labrina Barmpetaki, President of the PhARMA Innovation Forum (PIF), First Vice President of the Hellenic-American Chamber of Commerce, and Managing Director of AbbVie Greece, Cyprus & Malta, placed at the center of the 24th HealthWorld Conference, organized by the Hellenic-American Chamber of…
PhARMA Innovation (PIF) made a strong presence at the Bio3 Forum 2025 on Biotechnology, Bioinformatics & Bioeconomy, held on September 15–19 in Athens, under the theme “Fostering Collaboration in Industry & Academia.” The Forum served as a key reference point for the international scientific and business community, bringing together leading representatives from the pharmaceutical industry,…
A threat to patient access and public health PhARMA Innovation Forum (PIF) expresses its deep concern regarding the official data released by EKAPY (National Central Health Procurement Authority) – with a delay of more than a year – to our member companies. Once again, the figures reveal a complete derailment of the public budget for…
